Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

QUIA PHARMA

0.00 SEK

0.00 %

Less than 1K followers

QUIA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
0.00 %
-66.67 %
-73.68 %
-82.76 %
-88.28 %
-93.49 %
-99.98 %
-100.00 %
-100.00 %

QUIA PHARMA operates in medical technology. The company has developed a technological platform that is used to develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.

Read more
Market cap
1.97M SEK
Turnover
17.74K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

All
Press releases
3rd party
ShowingAll content types
Press release12/1/2025, 1:25 PM

Förtydligande av sista handelsdag samt tydliggörande kring fortsatt inriktning och avsaknad av koppling till “Quia PEG Intressenter”

QUIA PHARMA
Press release11/24/2025, 12:10 PM

Quia Pharma klargör avsikt inför avnotering

QUIA PHARMA
Regulatory press release11/18/2025, 7:30 AM

Lago Kapital säger upp marknadsgarantavtalet med Quia Pharma AB

QUIA PHARMA

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/17/2025, 3:30 PM

Avnotering av QUIA PHARMA AB (publ)

QUIA PHARMA
Regulatory press release10/29/2025, 11:00 AM

QUIA PHARMAs revisor begär eget utträde

QUIA PHARMA
Regulatory press release10/28/2025, 10:30 AM

QUIA PHARMA utser ny tf VD

QUIA PHARMA
Regulatory press release10/28/2025, 9:55 AM

Kommuniké från extra bolagsstämma 2025 i QUIA PHARMA AB (publ)

QUIA PHARMA
Regulatory press release10/21/2025, 3:20 PM

Avtal med Financial Recruitment uppsagt

QUIA PHARMA
Regulatory press release10/20/2025, 3:45 PM

Avtal med certified adviser uppsagt

QUIA PHARMA
Regulatory press release10/8/2025, 12:10 PM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I QUIA PHARMA AB (PUBL)

QUIA PHARMA
Regulatory press release10/8/2025, 7:45 AM

QUIA PHARMA avyttrar dotterbolag, upptar finansiering om 3 MSEK samt kallar till bolagsstämma för val av styrelse

QUIA PHARMA
Regulatory press release8/29/2025, 12:30 PM

QUIA PHARMA publicerar halvårsrapport för perioden 1 januari - juni 2025

QUIA PHARMA
Regulatory press release6/26/2025, 9:15 AM

Kommuniké från årsstämman 2025 i QUIA PHARMA AB (PUBL)

QUIA PHARMA
Regulatory press release6/13/2025, 12:08 PM

QUIA PHARMA MEDDELAR ATT BIO VITOS AS ÄNNU INTE HELT FULLGJORT SITT GARANTIÅTAGANDE I GENOMFÖRD FÖRETRÄDESEMISSION

QUIA PHARMA
Regulatory press release6/5/2025, 5:30 PM

QUIA PHARMA publicerar årsredovisningen för 2024, meddelar anmärkningar ur revisionsberättelsen samt informerar om nedskrivning om 4,45 MSEK

QUIA PHARMA
Regulatory press release5/26/2025, 5:15 PM

Kallelse till årsstämma i QUIA PHARMA AB (publ)

QUIA PHARMA
Regulatory press release5/23/2025, 5:55 AM

QUIA PHARMA skjuter upp publicering av årsredovisningen

QUIA PHARMA
Regulatory press release4/14/2025, 12:21 PM

Kommuniké från extra bolagsstämma 2025 i QUIA PHARMA AB (publ)

QUIA PHARMA
Regulatory press release4/11/2025, 3:22 PM

Quia Pharma meddelar aktieägares förslag till nya styrelseledamöter inför extra bolagsstämma

QUIA PHARMA
Press release4/10/2025, 1:55 PM

Quia Pharma erhåller notice of allowance för patent i Japan avseende ”releasable GLP-1 conjugates”

QUIA PHARMA
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.